- Home
- CVRX vs SLGL Comparison
CVRX vs SLGL Comparison
Compare CVRX & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVRX | SLGL |
|---|---|---|
| Founded | 2000 | 1997 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.7M | 159.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CVRX | SLGL |
|---|---|---|
| Price | $4.90 | $77.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $11.20 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 393.1K | 29.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.78 | $122.71 |
| Revenue Next Year | $19.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.30 | $4.02 |
| 52 Week High | $15.36 | $76.80 |
Technical Indicators
Market Signals| Indicator | CVRX | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 30.32 | 68.67 |
| Support Level | $4.37 | $62.08 |
| Resistance Level | $7.03 | $76.80 |
| Average True Range (ATR) | 0.56 | 7.03 |
| MACD | -0.18 | 0.77 |
| Stochastic Oscillator | 18.03 | 98.64 |
Price Performance
Historical ComparisonAbout CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.